The aim of this study was to determine whether pyrosequencing may be used to determine MGMT promoter methylation status using archival tissue samples from glioblastomas and to investigate the prognostic significance of MGMT promoter methylation in patients treated in the routine clinic with concurrent temozolomide and radiotherapy followed by adjuvant temozolomide. The gene discussed is MGMT; the disease is glioblastoma.